ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting

PHASE3CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

March 26, 2020

Primary Completion Date

October 7, 2021

Study Completion Date

November 1, 2021

Conditions
Lung NeoplasmsLung Cancer
Interventions
DRUG

OTL38 for Injection

Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL

DEVICE

Near infrared camera imaging system

Near infrared camera imaging system

Trial Locations (12)

15212

Allegheny General Hospital, Pittsburgh

15232

University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania, Philadelphia

22908

University of Virginia, Charlottesville

44195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor

55242

University of Iowa, Iowa City

55905

Mayo Clinic, Rochester

77030

MD Anderson Cancer Center, Houston

98109

Swedish Hospital, Seattle

06904

Stamford, Stamford

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Clinipace Worldwide

INDUSTRY

lead

On Target Laboratories, LLC

INDUSTRY